PRC
JAZZ icon

Pearl River Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Pearl River Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,613
Closed -$321K – 578
2023
Q4 		$321K Sell
2,613
-5,073
-66% -$633K 0.05% 392
2023
Q3 		$995K Buy
7,686
+5,322
+225% +$709K 0.16% 220
2023
Q2 		$293K Buy
+2,364
New +$318K 0.05% 401
2023
Q1 		– Sell
-4,946
Closed -$788K – 550
2022
Q4 		$788K Buy
4,946
+3,192
+182% +$468K 0.13% 245
2022
Q3 		$234K Buy
+1,754
New +$267K 0.04% 415
2020
Q1 		– Sell
-3,907
Closed -$583K – 612
2019
Q4 		$583K Buy
+3,907
New +$532K 0.22% 133

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Pearl River Capital's JAZZ Position: Q1 2024 in Review

Pearl River Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2024, closing a stake of 2,613 shares — an estimated $321K sold.

Pearl River Capital first reported a position in JAZZ in Q4 2019 and held it in 6 quarters. The position peaked at $995K in Q3 2023. 481 funds tracked by Wall St. Rank hold JAZZ as of Q1 2024.

  • Pearl River Capital reported no remaining Jazz Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Pearl River Capital sold 2,613 Jazz Pharmaceuticals shares in Q1 2024, an estimated $321K.
  • Pearl River Capital first reported a position in Jazz Pharmaceuticals in Q4 2019 and held it in 6 quarters.
  • Pearl River Capital's Jazz Pharmaceuticals position peaked at $995K in Q3 2023.
  • 481 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2024.

Based on Pearl River Capital's 13F filing for Q1 2024, filed 14 May 2024.